Commentary: The ascending aorta and arch in the sights of transcatheter
therapy. A time for reappraisal.
Abstract
The ascending aorta and arch have until recently been one of the last
bastions of cardiovascular surgery, where life-threatening diseases
impose the need for prompt correction and reversal of the impending
adverse prognosis. Though a disease where dogmatic recommendations
prevail, with upfront surgical intervention in the mind of every
physician, type A acute aortic dissection (AAD) is a subject still
blurred by many uncertainties. Endovascular intervention for the
treatment of type A AAD are rapidly progressing and utilization of
transcatheter therapies in the ascending aorta for treating type A AAD
has demonstrated technical success in small studies, low early mortality
rates, and relatively acceptable aorta-related mortality rates in the
long-term. These findings strengthen the preponderant role of the
endovascular heart surgeon on the management of these procedures, where
a combination of wire skill training and surgical proficiency
encompassing all technical options available makes it distinctive and
resourceful, able to provide complete resolution to each multicomponent
of this disease in one setting, besides the promptness to repair the
inherent complications that are to accompany these interventions.
Transcatheter procedures and open surgery are to coexist side by side
and to be regarded as complementary rather than competing. Substantial
more refinement and technological innovation will be necessary before
endovascular repair of type A AAD comes to widespread use, the ideal
timespan for cardiovascular surgeons to be involved, and prepared to
take on the challenges of leading this new enterprise.